Advanced search
1 file | 611.34 KB Add to list

Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer

Tom Van Maerken (UGent) , Ali Rihani (UGent) , Alan Van Goethem (UGent) , Anne De Paepe (UGent) , Franki Speleman (UGent) and Jo Vandesompele (UGent)
(2014) CANCER LETTERS. 344(2). p.157-165
Author
Organization
Keywords
p53, pediatric tumors, targeted therapy, MDM2, nutlin, ACUTE LYMPHOBLASTIC-LEUKEMIA, MOLECULE MDM2 ANTAGONISTS, CELL-CYCLE ARREST, TUMOR-SUPPRESSOR, UNITED-STATES, HEMATOLOGICAL MALIGNANCIES, SENSITIZES NEUROBLASTOMA, TRANSCRIPTIONAL ACTIVITY, RETINOBLASTOMA CELLS, ANTITUMOR-ACTIVITY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 611.34 KB

Citation

Please use this url to cite or link to this publication:

MLA
Van Maerken, Tom, Ali Rihani, Alan Van Goethem, et al. “Pharmacologic Activation of Wild-type P53 by Nutlin Therapy in Childhood Cancer.” CANCER LETTERS 344.2 (2014): 157–165. Print.
APA
Van Maerken, T., Rihani, A., Van Goethem, A., De Paepe, A., Speleman, F., & Vandesompele, J. (2014). Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. CANCER LETTERS, 344(2), 157–165.
Chicago author-date
Van Maerken, Tom, Ali Rihani, Alan Van Goethem, Anne De Paepe, Franki Speleman, and Jo Vandesompele. 2014. “Pharmacologic Activation of Wild-type P53 by Nutlin Therapy in Childhood Cancer.” Cancer Letters 344 (2): 157–165.
Chicago author-date (all authors)
Van Maerken, Tom, Ali Rihani, Alan Van Goethem, Anne De Paepe, Franki Speleman, and Jo Vandesompele. 2014. “Pharmacologic Activation of Wild-type P53 by Nutlin Therapy in Childhood Cancer.” Cancer Letters 344 (2): 157–165.
Vancouver
1.
Van Maerken T, Rihani A, Van Goethem A, De Paepe A, Speleman F, Vandesompele J. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. CANCER LETTERS. 2014;344(2):157–65.
IEEE
[1]
T. Van Maerken, A. Rihani, A. Van Goethem, A. De Paepe, F. Speleman, and J. Vandesompele, “Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer,” CANCER LETTERS, vol. 344, no. 2, pp. 157–165, 2014.
@article{4228968,
  author       = {{Van Maerken, Tom and Rihani, Ali and Van Goethem, Alan and De Paepe, Anne and Speleman, Franki and Vandesompele, Jo}},
  issn         = {{0304-3835}},
  journal      = {{CANCER LETTERS}},
  keywords     = {{p53,pediatric tumors,targeted therapy,MDM2,nutlin,ACUTE LYMPHOBLASTIC-LEUKEMIA,MOLECULE MDM2 ANTAGONISTS,CELL-CYCLE ARREST,TUMOR-SUPPRESSOR,UNITED-STATES,HEMATOLOGICAL MALIGNANCIES,SENSITIZES NEUROBLASTOMA,TRANSCRIPTIONAL ACTIVITY,RETINOBLASTOMA CELLS,ANTITUMOR-ACTIVITY}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{157--165}},
  title        = {{Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer}},
  url          = {{http://dx.doi.org/10.1016/j.canlet.2013.11.002}},
  volume       = {{344}},
  year         = {{2014}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: